ANIK

Anika Therapeutics Inc

Health Care · USD

ANIK

Price

$14.76

-3.02%

Cap

$198M

Earnings

3/4 beat

30d Trend

-3%

ANIK
Loading chart data...
0 days · % change from startPowered by Brain47
52-week range91%
7.8715.48

Near 52-week highs — limited upside before resistance

Analyst consensus (3 analysts)+19% to target
1 Strong Buy1 Buy0 Hold1 Sell0 Strong Sell

Target range: $17$18 (consensus: $17.5)

Consensus: Moderate Buy

Earnings history

Q4 2025

BEAT

0.31 vs 0.02

Q3 2025

MISS

-0.22 vs

Q2 2025

BEAT

0.31 vs

Q1 2025

BEAT

0.12 vs

VolatilityHigh

Key macro factors

·

Global economic challenges affecting healthcare spending and consumer discretionary income for elective procedures and treatments.

·

Inflation and supply chain pressures impacting manufacturing, raw material (e.g., hyaluronic acid), and distribution costs for medical devices and therapeutics.

·

Evolving healthcare policies, insurance coverage, and reimbursement rates for orthopedic and pain management solutions, which can directly influence product demand and revenue.

Anika Therapeutics, Inc. is a global joint preservation company focused on early intervention orthopedic care, specializing in osteoarthritis (OA) pain management and regenerative solutions based on hyaluronic acid and implant technologies.

Next earnings:2026-05-08

QUANT SCORE

Building intelligence for this stock. Brain47 needs a few days of price data to calculate technical indicators and generate a full quant score.

Want full analysis on every stock?

Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.

Join Brain47 — Free

Generated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.

Anika Therapeutics Inc (ANIK) — Brain47 AI Score 55/100 | Analysis